about
[Treatment of thrombotic microangiopathies][Common variable immunodeficiency with autoimmune manifestations: study of nine cases; interest of a peripheral B-cell compartment analysis in seven patients].International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.[Classical anticoagulant treatment of venous thromboembolic disease in cancer patients. Apropos of a retrospective study of 71 patients].Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group.Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives.[Acute pericarditis associated with Plasmodium ovale malaria].Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study.Fever and deep venous thrombosis. Findings from the RIETE registry.[Diagnostic kit for febrile headache!...].[Malignant cardiac tumors].[Spontaneous portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent patient].Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma.Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.Stopping HABITS.[Gemcitabine-induced thrombotic microangiopathy].Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers.Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.[Treatment of hot flashes in women with a previous diagnosis of breast cancer].[Subacute meningoradiculomyeloencephalitis due to cryptococcosis infection].[Cardiotoxicity of 5-fluorouracil].[Cardiac prevention: the oncologic point of view].[Treatment of venous thromboembolic disease in cancer patients].Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.Frequency of anticardiolipin, antinuclear and anti beta2GP1 antibodies is not increased in unselected epileptic patients: a case-control study.Genetic abnormalities in synovial sarcoma.A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.Venous thromboembolism prophylaxis in patients undergoing abdominal or pelvic surgery for cancer--a real-world, prospective, observational French study: PRéOBS.Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study.[A finger osteolysis].A Serologic Marker of Paraneoplastic Limbic and Brain-Stem Encephalitis in Patients with Testicular CancerEndometriosis and non-Hodgkin's lymphoma[Ossified bronchial neuroendocrine tumors: 3 cases][Therapeutic intensification and autotransplantation of hematopoietic stem cells in metastatic breast cancers][Herpes zoster meningoradiculitis in AIDS][Autoimmune neutropenia and thrombopenia in Hodgkin disease]
P50
Q33330458-935D1854-E553-4550-AA1B-0CA9BC4B251AQ33364981-2FE25EF6-1E61-498E-916F-BBAECAF649FCQ33404714-A5890543-2BDC-4435-9A24-22C3240E7809Q33440884-DA97BA2B-D2BE-4F6E-B454-937F19EAC39DQ33496434-C60C6789-AEB9-4C80-A93E-8A7B0BB15264Q33561213-86283158-3B11-4138-A268-F35F33D615ABQ36195033-C699DF10-8FBA-445B-8B7C-AD94353302AAQ37518908-BF60452E-D766-4253-AC97-D3C34C000195Q37607833-A3FE1017-8964-4871-BE9E-57666B353748Q38435428-9B120E23-9B33-4350-8E47-4C5C6C7CCCD8Q38463661-A4E782A8-9D40-4FAE-8E54-44CAFB41E449Q39171173-EB0445C9-7863-4215-9BDF-16DC49B16B7DQ40320611-A06E83C7-A263-49E3-91D0-84EC1F8EF6C0Q40499966-5E4D0365-F23A-4852-A8D3-CA7A0DDE8FB0Q40508287-A666AC49-67C8-41D9-8AA2-243C820B186EQ40590336-CC0582CD-7985-4ACF-891C-C40983C3C434Q40644232-AD39781F-A822-43ED-8E14-244BCE5F666AQ41104034-46726294-F66F-4C26-8E27-DE5BF8D56DB3Q43981504-639217B1-B3BB-4B7E-A593-C6A0C1E0AA60Q44082984-1C12F2C4-E05B-4BB8-A354-2B79FC8EDC00Q44208072-C22C217A-972F-4DAA-BAA9-259D7F27F78AQ44823539-EBECB97D-7006-407E-983E-49EBE3F57081Q44969905-BE845375-F514-431E-A5D1-DE19C5D9DFF5Q46489488-79B25F8D-7B74-4877-9134-581AFDD23745Q46495508-09C8DA69-E886-42BC-979A-84D9D9C69EC8Q46495520-0646059C-A421-427A-9A00-9E839AAE7E0DQ46659691-4539CC41-01AA-4984-AC11-A26F59298ABFQ47574970-3DDDE173-F75E-49D8-886C-EE5D31D599C9Q47665064-F04091BC-48C3-40A9-B63E-237E3E95A903Q48005096-8388C4D6-A6EF-417C-AB0D-F0331D5D2D42Q50620456-7D2B4A96-FA21-4C65-BDF8-4F200E8F27B4Q51772514-5316ADE2-1303-490E-A734-E65A62A8A4F6Q53091126-EA704D1D-570B-4070-8C48-706DF36E8893Q54262462-0C1CACA8-AD55-4B9F-80FD-499256A47495Q57256359-78C0A45A-3A8E-46DF-976B-B37917FC2E9CQ57579822-B7E61591-13A0-4A78-864F-026CB038D99CQ71361724-69B38648-9B0F-4BFC-A7CB-87439F5EB80BQ71931234-3E0724D5-F5B7-487D-B2F7-61D6D4CADA4CQ72205903-AA2D379D-6255-45D5-81BA-573B33C120FCQ72205992-73224C05-FD8D-4F53-BC85-C6BF99CB926D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philippe Debourdeau
@ast
Philippe Debourdeau
@en
Philippe Debourdeau
@es
Philippe Debourdeau
@nl
type
label
Philippe Debourdeau
@ast
Philippe Debourdeau
@en
Philippe Debourdeau
@es
Philippe Debourdeau
@nl
prefLabel
Philippe Debourdeau
@ast
Philippe Debourdeau
@en
Philippe Debourdeau
@es
Philippe Debourdeau
@nl
P106
P31
P496
0000-0003-3761-9264